LENSAR (NASDAQ:LNSR – Get Free Report) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its peers? We will compare LENSAR to similar companies based on the strength of its earnings, profitability, analyst recommendations, dividends, institutional ownership, risk and valuation.
Profitability
This table compares LENSAR and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| LENSAR | 56.07% | 1,254.25% | 49.13% |
| LENSAR Competitors | -303.57% | -175.14% | -22.20% |
Analyst Ratings
This is a summary of current ratings and price targets for LENSAR and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LENSAR | 1 | 0 | 2 | 0 | 2.33 |
| LENSAR Competitors | 4291 | 10580 | 18364 | 831 | 2.46 |
Institutional and Insider Ownership
40.1% of LENSAR shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 65.8% of LENSAR shares are owned by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares LENSAR and its peers gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| LENSAR | $58.44 million | -$34.28 million | -11.75 |
| LENSAR Competitors | $1.87 billion | $136.27 million | 5.88 |
LENSAR’s peers have higher revenue and earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
LENSAR has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, LENSAR’s peers have a beta of 2.57, meaning that their average share price is 157% more volatile than the S&P 500.
Summary
LENSAR peers beat LENSAR on 7 of the 13 factors compared.
About LENSAR
LENSAR, Inc. is a medical technology company focused on ophthalmic laser systems used in cataract surgery and other procedures involving the eye. The company develops and commercializes femtosecond laser technology designed to assist surgeons with key steps of cataract surgery, including corneal incisions, capsulotomy and lens fragmentation. Its product portfolio includes the LENSAR Laser System, which incorporates image-guidance and planning technologies intended to support precise, customized procedures.
Receive News & Ratings for LENSAR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENSAR and related companies with MarketBeat.com's FREE daily email newsletter.
